David E. Gerber, MD
University of Texas Southwestern Medical CenterDallas, TX
Department of Internal Medicine (Division of Hematology-Oncology), Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Authored Items
Simon Craddock Lee, PhD, MPH, Heidi A. Hamann, PhD, Magalis Z. Tijerina, BA, Cynthia Ortiz, MPH, Claudia Chavez, MBA, Noel Santini, MD, David E. Gerber, MD
November 9, 2018 | November 2018 Vol 9, NO 11
While adherence to annual screening exceeded 90% in the National Lung Screening Trial, the trial population was disproportionately white, educated, and received care in the tightly controlled environment of a clinical trial.
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
November 9, 2018 | November 2018 Vol 9, NO 11
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
June 17, 2013 | April 2013 Vol 4, No 2
Since the publication of the positive results of the National Lung Screening Trial (NLST)—the first lung cancer screening trial to demonstrate a reduction in lung cancer mortality—in the New England Journal of Medicine in 2011, several uncertainties regarding implementation of widespread lung cancer screening have arisen.
Last modified: December 19, 2018